Iovance Reports 24.6% Response Rate in mNSCLC Trial
Iovance reported a 24.6% response rate in previously treated non-squamous mNSCLC and a 59.1% rate in a biomarker-enriched subgroup.
Related stories
Nostrum Oil & Gas Shares Fall 8% on LSE Cancellation Plan
Nostrum Oil & Gas shares are down 8% after a plan to cancel its London Stock Exchange listing.
M impact | EQUITY | Oct 30, 2026, 08:08 AM UTC
Reddit Shares Fall 22% Premarket as CEO Warns of Q4 Visitor Decline
Reddit’s CEO warned that total daily active unique visitors could fall by a double-digit percentage in Q4. Shares fell 22% premarket.
M impact | EQUITY | Oct 30, 2026, 08:07 AM UTC
EU semiconductor shares fall 2%-5%
M impact | EQUITY | Oct 30, 2026, 08:06 AM UTC
Tokyo Electron Sees Robust Profit Growth Amid AI Return Concerns
M impact | EQUITY | Oct 30, 2026, 08:05 AM UTC
Amazon shares fall 7.4% premarket after Q4 revenue forecast misses estimates
M impact | EQUITY | Oct 30, 2026, 08:04 AM UTC
Sanofi shares gain after results
Sanofi shares rose following its results.
M impact | EQUITY | Oct 30, 2026, 08:04 AM UTC